These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23689569)

  • 1. Treatment of progressive IgA nephropathy: an update.
    Wang W; Chen N
    Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the treatment of IgA nephropathy.
    Barbour S; Feehally J
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):319-326. PubMed ID: 28399021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of IgA nephropathy: an update.
    Rosselli JL; Thacker SM; Karpinski JP; Petkewicz KA
    Ann Pharmacother; 2011 Oct; 45(10):1284-96. PubMed ID: 21954446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
    Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of IgA nephropathy with chronic renal failure].
    Pozzi C
    G Ital Nefrol; 2008; 25 Suppl 44():83-7. PubMed ID: 19048591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapy for IgA nephropathy.
    Floege J; Eitner F
    J Am Soc Nephrol; 2011 Oct; 22(10):1785-94. PubMed ID: 21903997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgA nephropathy patients with partial crescent formation benefit from immunosuppressants: evidence from repeat renal biopsy.
    Luo MN; Pan Q; Huang ZQ; Li SM; Xu YZ; Liu HF
    Discov Med; 2020; 30(159):19-25. PubMed ID: 33357359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pathological manifestations of Chinese childhood patients with primary IgA nephropathy: a national collaborative study of 33 hospitals].
    ; Jiang XY
    Zhonghua Er Ke Za Zhi; 2007 Apr; 45(4):272-8. PubMed ID: 17706064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of IgA nephropathy].
    Amoroso L; De Sanctis L; Cappelli P; Di Vito R; Sirolli V; Bonomini M
    G Ital Nefrol; 2011; 28(6):622-32. PubMed ID: 22167613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
    Zhang Q; Shi SF; Zhu L; Lv JC; Liu LJ; Chen YQ; Zhang H; Wang HY
    Am J Nephrol; 2012; 35(4):312-20. PubMed ID: 22456060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
    Rasche FM; Keller F; Lepper PM; Aymanns C; Karges W; Sailer LC; Müller Lv; Czock D
    Clin Exp Immunol; 2006 Oct; 146(1):47-53. PubMed ID: 16968397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of IgA nephropathy.
    Barratt J; Feehally J
    Kidney Int; 2006 Jun; 69(11):1934-8. PubMed ID: 16641928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary IgA nephropathy in elderly patients.
    Cheungpasitporn W; Nasr SH; Thongprayoon C; Mao MA; Qian Q
    Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure.
    Chan LY; Leung JC; Lai KN
    Clin Exp Nephrol; 2004 Dec; 8(4):297-303. PubMed ID: 15619027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of IgA nephropathy: Recent advances and prospects.
    Coppo R
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course and treatment of IgA nephropathy.
    Mustonen J; Syrjänen J; Rantala I; Pasternack A
    J Nephrol; 2001; 14(6):440-6. PubMed ID: 11783599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T; Najafi I; Salimi BH; Broomand B
    Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.